The opening ceremony for TBG Biotechnology Xiamen Inc., a Medigen subsidiary was held on Monday, November 10th, 2014 in Xiamen Haicang Bio Bay Biomedicine Port. The ceremony has renowned guests from Taiwan’s healthcare and biotech industry leaders including Dr. Ching-Chuan Yeh, Prof. Jaw-Jou Kang and Dr. John Hsuan (Min-Chih Hsuan), as well as government officials and bankers from Fujian province and Xiamen City in China.
This important strategic re-entrance of TBG to Greater China has gone through two years of preparation with detailed evaluation followed by Perkin Elmer’s acquisition of Medigen’s Shanghai Haoyuan Corp. back in 2012. Building on its core technologies of IVD related nucleic acid testing kits and service, TBG has widen its business scope to infectious diseases, in vitro detection of antibody-antigen, cancer genetic testing and other personalized medicine treatments.
This investment plan of Medigen has been approved by Investment Commission, MOEA in November 2013. Xiamen Haichang Bio Bay provides incentives in R&D, tax, rental subsidy as well as numerous favorable conditions for Medigen to station in its Biomedicine Port.
